Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Heart failure experts agree: HFmrEF should not be ignored
Data on the treatment and management of HFmrEF are limited, but a new scientific statement from the Heart Failure Society of America highlights how important it is to take this condition seriously.
Medtronic leads $100M investment in artery denervation company
Pulnovo Medical, a global medtech company, plans on using the funds for clinical development, regulatory submissions, commercialization and much more.
FDA clears new AI model for detecting signs of cardiac amyloidosis
This is the second FDA clearance in two weeks for Massachusetts-based Anumana. The company's AI models are built to evaluate ECG results for signs of various cardiovascular conditions.
New gene therapy may help protect the hearts of patients with Friedreich's ataxia
A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.
FDA confirms another recall for Johnson & Johnson’s Impella heart pumps
More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.

doctor patient elderly check up hospital

Heart failure experts agree: HFmrEF should not be ignored

Data on the treatment and management of HFmrEF are limited, but a new scientific statement from the Heart Failure Society of America highlights how important it is to take this condition seriously.

pulmonary hypertension denervation pulnovo medical

Medtronic leads $100M investment in artery denervation company

Pulnovo Medical, a global medtech company, plans on using the funds for clinical development, regulatory submissions, commercialization and much more.

artificial intelligence AI heart cardiology

FDA clears new AI model for detecting signs of cardiac amyloidosis

This is the second FDA clearance in two weeks for Massachusetts-based Anumana. The company's AI models are built to evaluate ECG results for signs of various cardiovascular conditions.

Video interview with Ronald Crystal, MD, chair, Department of Genetic Medicine at Weill Cornell Medicine, presented late-breaking findings on a first in-human, virus-delivered gene therapy trial to stop cardiomyopathy death in patients with Friedreich Ataxia (FA). #ACC #ACC26

New gene therapy may help protect the hearts of patients with Friedreich's ataxia

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

FDA confirms another recall for Johnson & Johnson’s Impella heart pumps

More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.

FDA sees promise in voice-based AI model for heart failure

An advanced algorithm that looks for signs of heart failure in five-second voice recordings has received the FDA's breakthrough device designation.

artificial intelligence AI in healthcare

Early use of tirzepatide after heart attack or stroke linked to key cardiovascular benefits

When patients without diabetes land in the hospital after a heart attack or stroke, early treatment with tirzepatide may prove beneficial.

A single injection of saNppa lipid nanoparticles enables self-amplification and high-yield pro-ANP production for more than 28 days. Circulating pro-ANP is selectively cleaved by the cardiac protease corin into active ANP, activating NPR1/cGMP signaling in the heart. Image courtesy of Science, Kaiyue Zhang et al. https://www.science.org/doi/10.1126/science.adu9394

Single injection could help heal heart attack damage

Amplifying the body’s natural release of a specific hormone may reduce stress on the heart and limit long‑term damage after myocardial infarctions.